CClinicalTrials.gg
CompletedNCT07830459Updated Sep 21, 2026

Caffeine Dose and Duration in Habitual Female Users

An interventional study of Caffeine 3 mg/kg and Caffeine 6 mg/kg in Caffeine, Athletic Performance and Resistance Traaining, sponsored by Birjand University of Medical Sciences. Completed at 1 site in Iran. Open to female participants aged 20 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Birjand University of Medical Sciences · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
20 Years to 30 Years
Sex
Female
01

Study summary

This study compares the effects of acute (single-session) and short-term (7-day) consumption of different doses of caffeine (3 and 6 mg/kg) on maximal strength, strength endurance, vertical jump, and medicine ball throw performance in habitual caffeine-consuming women (daily intake of 5 mg/kg). Thirty-six resistance-trained women were randomly assigned to three groups: 3 mg/kg caffeine, 6 mg/kg caffeine, or placebo in a double-blind crossover design. Participants completed both acute (60 min pre-exercise) and short-term (7 consecutive days) protocols. The main findings showed that acute ingestion of 6 mg/kg caffeine impaired peak power in the maximal strength test, while short-term consumption of the same dose improved peak power in the strength-endurance test. The 3 mg/kg dose was ineffective in all conditions. Caffeine did not affect jump or throw performance. The study highlights the need for individualized caffeine guidelines based on timing, dosage, and habituation status.

02

Conditions studied

  • Caffeine
  • Athletic Performance
  • Resistance Traaining
03

Who can participate

Ages eligible
20 Years to 30 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

Absence of neuromuscular and musculoskeletal disorders

At least 2 years of regular resistance training experience (minimum 3 sessions per week)

At least 6 months of resistance training prior to enrollment

Absence of renal and hepatic disorders

Daily caffeine consumption of 5 mg/kg body weight (based on questionnaire)

No use of specific medications or supplements that could affect study outcomes (e.g., beta-alanine, creatine, pre-workout supplements) -

Exclusion criteria

Exclusion Criteria:

Occurrence of any injury during the study

Failure to adhere to the supplement consumption protocol

Withdrawal from the study-

04

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Caffeine 3 mg/kg

    Participants received 3 mg/kg body weight of caffeine powder in gelatin capsules daily for 7 days. Acute consumption: 60 minutes before testing. Short-term consumption: 7 consecutive days

    Dietary Supplement: Caffeine 3 mg/kg

  • Experimental
    Caffeine 6 mg/kg

    Participants received 6 mg/kg body weight of caffeine powder in gelatin capsules daily for 7 days. Acute consumption: 60 minutes before testing. Short-term consumption: 7 consecutive days

    Dietary Supplement: Caffeine 6 mg/kg

  • Placebo comparator
    Placebo

    Participants received identical capsules containing flour, consumed daily for 7 days

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementCaffeine 3 mg/kg

    Caffeine powder (99% purity) encapsulated in gelatin capsules at a dose of 3 mg per kilogram of body weight. The capsules are identical in appearance, odor, and taste to the placebo. Participants consume the capsules daily for 7 consecutive days. On the testing day, the capsules are ingested 60 minutes prior to the exercise tests.

  • Dietary supplementCaffeine 6 mg/kg

    Caffeine powder (99% purity) encapsulated in gelatin capsules at a dose of 6 mg per kilogram of body weight. The capsules are identical in appearance, odor, and taste to the placebo. Participants consume the capsules daily for 7 consecutive days. On the testing day, the capsules are ingested 60 minutes prior to the exercise tests.

  • Dietary supplementPlacebo

    Placebo capsules containing inert flour (or microcrystalline cellulose), identical in appearance, odor, and taste to the caffeine capsules. Participants consume the capsules daily for 7 consecutive days. On the testing day, the capsules are ingested 60 minutes prior to the exercise tests.

05

What researchers measure

Primary outcomes

  1. Change in Peak Power (PP) During Maximal Strength Test

    Peak concentric power (Watts) during 1-RM bench press test, measured using a validated Kinect camera

    Time frame: Baseline, 60 minutes post-ingestion (acute), and after 7 days of supplementation (short-term)

Secondary outcomes

  1. Change in Peak Power During Strength-Endurance Test

    eak concentric power (Watts) during bench press at 50% of 1-RM to failure, measured using Kinect camera

    Time frame: Baseline, 60 minutes post-ingestion (acute), and after 7 days of supplementation (short-term)

  2. Change in Medicine Ball Throw Distance

    Distance (cm) of 3-kg medicine ball throw from chest position

    Time frame: Baseline, 60 minutes post-ingestion (acute), and after 7 days of supplementation (short-term)

  3. Change in Vertical Jump Height

    Countermovement jump height (cm) measured using Kinect camera

    Time frame: Baseline, 60 minutes post-ingestion (acute), and after 7 days of supplementation (short-term)

  4. Change in Number of Repetitions (Strength-Endurance)

    Number of repetitions performed at 50% of 1-RM until failure

    Time frame: Baseline, 60 minutes post-ingestion (acute), and after 7 days of supplementation (short-term)

06

Study locations

1 site
  • Faculty of Sport Sciences, University of Birjand
    Birjand, South Khorasan Province 9717434765, Iran
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07830459
Lead sponsor
Birjand University of Medical Sciences
Responsible party
Mohsen mohammadnia ahmadi (Assistant Professor of Exercise Physiology, Birjand University of Medical Sciences) — Principal investigator
First posted
Sep 21, 2026
Start date
Feb 12, 2023
Primary completion
Mar 20, 2023
Completion
Mar 30, 2023
Last update
Sep 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion